| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049203101 |
| P356 | DOI | 10.1038/JP.2008.185 |
| P698 | PubMed publication ID | 19020527 |
| P5875 | ResearchGate publication ID | 23484576 |
| P50 | author | Pracha Nuntnarumit | Q47883290 |
| P2093 | author name string | A Khositseth | |
| P Thanomsingh | |||
| P2860 | cites work | Indomethacin for asymptomatic patent ductus arteriosus in preterm infants | Q24250190 |
| Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited | Q31096864 | ||
| Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome | Q31928465 | ||
| How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? | Q35032172 | ||
| Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure | Q35144061 | ||
| Severity of the ductal shunt: a comparison of different markers | Q35297500 | ||
| Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants | Q35540152 | ||
| Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis | Q35577606 | ||
| Normal values of B type natriuretic peptide in infants, children, and adolescents | Q35581437 | ||
| Essential biochemistry and physiology of (NT-pro)BNP. | Q35677297 | ||
| Treatment of patent ductus arteriosus | Q35682590 | ||
| Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? | Q35911299 | ||
| Clinical value of NT-ProBNP and BNP in pediatric cardiology | Q36158173 | ||
| Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction | Q37108057 | ||
| Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure | Q40618681 | ||
| Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants | Q42079680 | ||
| N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study | Q43137708 | ||
| Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial | Q45164616 | ||
| Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair | Q46763875 | ||
| Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants | Q47265567 | ||
| Use of NT-proBNP in routine testing and comparison to BNP. | Q48030186 | ||
| Plasma Concentrations of Aminoterminal Pro Atrial Natriuretic Peptide and Aminoterminal Pro Brain Natriuretic Peptide in Healthy Neonates: Marked and Rapid Increase After Birth | Q48181927 | ||
| Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants | Q48562086 | ||
| Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates | Q48731820 | ||
| Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants | Q49086969 | ||
| Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. | Q51665936 | ||
| Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth | Q52206851 | ||
| Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage | Q57794298 | ||
| Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants | Q57794316 | ||
| Sensitivity, specificity and predictive value of clinical findings, m-mode echocardiography and continuous-wave Doppler sonography in the diagnosis of symptomatic patent ductus arteriosus in preterm infants | Q68148904 | ||
| Patent ductus arteriosus in neonates with severe respiratory disease | Q71361699 | ||
| Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus | Q71722340 | ||
| A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus | Q72443704 | ||
| The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates | Q80389755 | ||
| N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus | Q80546454 | ||
| Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP) | Q83976702 | ||
| P433 | issue | 2 | |
| P921 | main subject | patent ductus arteriosus | Q2072063 |
| preterm infant | Q45051448 | ||
| P304 | page(s) | 137-142 | |
| P577 | publication date | 2008-11-20 | |
| P1433 | published in | Journal of Perinatology | Q18626659 |
| P1476 | title | N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants | |
| P478 | volume | 29 |
| Q41713582 | B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants |
| Q84311229 | Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment |
| Q90098359 | Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation |
| Q58739837 | Effects of prophylactic oral ibuprofen on the closure rate of patent ductus arteriosus in premature infants |
| Q37864597 | N-terminal pro-brain natriuretic peptide level as a screening tool for cardiac involvement in paediatric diseases of extracardiac origin |
| Q37055084 | N-terminal pro-brain natriuretic peptide measurements in hemodynamically significant patent ductus arteriosus in preterm infants |
| Q51582870 | N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants. |
| Q41815458 | NT-proBNP Levels Improve the Ability of Predicting a Hemodynamically Significant Patent Ductus Arteriosus in Very Low-Birth-Weight Infants |
| Q37451050 | Patent ductus arteriosus in preterm infants: do we have the right answers? |
| Q48736326 | Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life. |
| Q33580726 | The Use of N-Terminal-Pro-BNP in Preterm Infants |
| Q87246873 | The relationship between BNP, NTproBNP and echocardiographic measurements of systemic blood flow in very preterm infants |
| Q48457621 | Urinary NT-proBNP and ductal closure in preterm infants |
| Q48113556 | Urinary NT-proBNP levels and echocardiographic parameters for patent ductus arteriosus |
| Q47333874 | Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants |
| Q38026430 | Use of cardiac biomarkers in neonatology |
Search more.